~~<i id='999BB35483'><strike id='999BB35483'><tt id='999BB35483'><pre id='999BB35483'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

author：Wikipedia 2025-09-30 22:10:06 - browse：74876

MADRID — Merck is paying billions of dollars to partner with Daiichi Sankyo on a series of cancer drugs, underscoring the excitement around targeted chemotherapy treatments.

The deal includes a $4 billion upfront payment and an additional $1.5 billion over the next two years. Up to $16.5 billion more is on the table depending on the success of the drugs in development.

The announcement on Thursday night in the United States came on the eve of one the cancer field’s biggest annual conferences, the European Society for Medical Oncology Congress, being held this year in Madrid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Humana’s losses in Medicare Advantage tank its stock

leisure time

focus

explore

focus

hotspot

AllenInstituteCEORuiCostaCourtesyAllenInstituteMappingthebillionsofcellsthatmakeupthebrainisataskmam

WSS

Biogen walks away from Aduhelm, years after polarizing approval

Reconstructing family trees of blood cells may help predict disease

Why you shouldn’t ask, “What country has the best health care?”

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Medicare drug price negotiation legal challenge met with skepticism

STAT Virtual Event: JPM Recap, Live!

hotspot

hotspot

leisure time

Medical leaders decry Supreme Court decision on affirmative action

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Duchenne breakthrough therapy leaves behind pioneering families

STAT Virtual Event: JPM Recap, Live!

Medical leaders decry Supreme Court decision on affirmative action

New clues to why women have higher risk of autoimmune disorders

The cancer drug shortage isn’t new — and neither are the solutions

Study suggests new cause of Down syndrome: cells linked to aging

Apple is now the first public company to be valued at $3 trillion

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

focus

Arena BioWorks launches in Cambridge to speed drug discovery

Profiling embryos to choose those with higher IQs is almost a reality

Why Medicare shouldn’t cover every FDA

Zyn nicotine pouches become unlikely player in latest culture war

Study suggests new cause of Down syndrome: cells linked to aging

Merck to acquire Harpoon Therapeutics for $680 million

explore

explore

focus

hotspot